首页> Leukemia and lymphoma> Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.

Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.

导出原文传递

翻译打印收藏纠错

第一作者： Ngo BT

作者： Ngo BT ^[1] ; Felthaus J ; Hein M ; Follo M ; Wider D ; Ihorst G ; Engelhardt M ; Wasch R

作者单位： Department of Hematology and Oncology, University Medical Center, Freiburg, Germany. ^[1]

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Leukemia and lymphoma

2010年51卷9期

1632-1642页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Leukemia and lymphoma

2010年51卷9期

1632-1642页

检索历史清除

Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.

Leukemia and lymphoma

相似文献

同项目论文

Leukemia and lymphoma

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.

Leukemia and lymphoma

相似文献

同项目论文

Leukemia and lymphoma

相关期刊

检索历史清除